These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 28574733)

  • 1. Mechanistic investigation of mixing and segregation of ordered mixtures: experiments and numerical simulations.
    Sarkar S; Minatovicz B; Thalberg K; Chaudhuri B
    Drug Dev Ind Pharm; 2017 Oct; 43(10):1677-1685. PubMed ID: 28574733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a Rational Design Space for Optimizing Mixing Conditions for Formation of Adhesive Mixtures for Dry-Powder Inhaler Formulations.
    Sarkar S; Minatovicz B; Thalberg K; Chaudhuri B
    J Pharm Sci; 2017 Jan; 106(1):129-139. PubMed ID: 27546350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug-lactose binding aspects in adhesive mixtures: controlling performance in dry powder inhaler formulations by altering lactose carrier surfaces.
    Zhou QT; Morton DA
    Adv Drug Deliv Rev; 2012 Mar; 64(3):275-84. PubMed ID: 21782866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Agglomerate behaviour of fluticasone propionate within dry powder inhaler formulations.
    Le VN; Robins E; Flament MP
    Eur J Pharm Biopharm; 2012 Apr; 80(3):596-603. PubMed ID: 22198291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preparation and Evaluation of Surface Modified Lactose Particles for Improved Performance of Fluticasone Propionate Dry Powder Inhaler.
    Singh DJ; Jain RR; Soni PS; Abdul S; Darshana H; Gaikwad RV; Menon MD
    J Aerosol Med Pulm Drug Deliv; 2015 Aug; 28(4):254-67. PubMed ID: 25517187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Formulating powder-device combinations for salmeterol xinafoate dry powder inhalers.
    Hassoun M; Ho S; Muddle J; Buttini F; Parry M; Hammond M; Forbes B
    Int J Pharm; 2015 Jul; 490(1-2):360-7. PubMed ID: 25987210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Controlling the performance of adhesive mixtures for inhalation using mixing energy.
    Thalberg K; Papathanasiou F; Fransson M; Nicholas M
    Int J Pharm; 2021 Jan; 592():120055. PubMed ID: 33176199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insights into the roles of carrier microstructure in adhesive/carrier-based dry powder inhalation mixtures: Carrier porosity and fine particle content.
    Shalash AO; Molokhia AM; Elsayed MM
    Eur J Pharm Biopharm; 2015 Oct; 96():291-303. PubMed ID: 26275831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multicomponent granular mixing in a Bohle bin Blender-Experiments and simulation.
    Sen K; Velez N; Anderson C; Drennen Iii JK; Zidan AS; Chaudhuri B
    Int J Pharm; 2020 Mar; 578():119131. PubMed ID: 32057888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Towards quantitative prediction of the performance of dry powder inhalers by multi-scale simulations and experiments.
    Nguyen D; Remmelgas J; Björn IN; van Wachem B; Thalberg K
    Int J Pharm; 2018 Aug; 547(1-2):31-43. PubMed ID: 29792988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A critical view on lactose-based drug formulation and device studies for dry powder inhalation: which are relevant and what interactions to expect?
    de Boer AH; Chan HK; Price R
    Adv Drug Deliv Rev; 2012 Mar; 64(3):257-74. PubMed ID: 21565232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Device Design and Formulation on the In Vitro Comparability for Multi-Unit Dose Dry Powder Inhalers.
    Shur J; Saluja B; Lee S; Tibbatts J; Price R
    AAPS J; 2015 Sep; 17(5):1105-16. PubMed ID: 25956383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polymer coating of carrier excipients modify aerosol performance of adhered drugs used in dry powder inhalation therapy.
    Traini D; Scalia S; Adi H; Marangoni E; Young PM
    Int J Pharm; 2012 Nov; 438(1-2):150-9. PubMed ID: 22964399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DEM analysis of the effect of particle-wall impact on the dispersion performance in carrier-based dry powder inhalers.
    Yang J; Wu CY; Adams M
    Int J Pharm; 2015 Jun; 487(1-2):32-8. PubMed ID: 25845718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Investigating mixing and segregation using discrete element modelling (DEM) in the Freeman FT4 rheometer.
    Yan Z; Wilkinson SK; Stitt EH; Marigo M
    Int J Pharm; 2016 Nov; 513(1-2):38-48. PubMed ID: 27596114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Numerical Modelling of Agglomeration and Deagglomeration in Dry Powder Inhalers: A Review.
    Yang J; Wu CY; Adams M
    Curr Pharm Des; 2015; 21(40):5915-22. PubMed ID: 26446462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dry powder inhalers: mechanistic evaluation of lactose formulations containing salbutamol sulphate.
    Kaialy W; Ticehurst M; Nokhodchi A
    Int J Pharm; 2012 Feb; 423(2):184-94. PubMed ID: 22197772
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lactose characteristics and the generation of the aerosol.
    Pilcer G; Wauthoz N; Amighi K
    Adv Drug Deliv Rev; 2012 Mar; 64(3):233-56. PubMed ID: 21616107
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Air permeability of powder: a potential tool for Dry Powder Inhaler formulation development.
    Le VN; Robins E; Flament MP
    Eur J Pharm Biopharm; 2010 Nov; 76(3):464-9. PubMed ID: 20854906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dissolution rate enhancement of piroxicam by ordered mixing.
    Saharan VA; Choudhury PK
    Pak J Pharm Sci; 2012 Jul; 25(3):521-33. PubMed ID: 22713937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.